SavedAdd your journal

Journals / Güncel Retina Dergisi / 2019 / Cilt: 3 - Sayı: 1

Emerging Therapies for the Treatment of Central Retinal Vein Occlusion and Macular Edema

Santral Retinal Ven Tıkanıklığı ve Maküla Ödemi Tedavisinde Yeni Geliştirilmekte Olan Tedaviler

Murat Serkan SONGUR
MEHMET ÇITIRIK
Pages
56–59
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this review, treatments and new applications other than anti-VEGF, steroids and laser used in the treatment of central retinal vein occlusion and macular edema will be reviewed.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Many agents are used in the current treatment of central retinal vein occlusion and its complications.
📊
Key Findings & Data:These treatments include anti- VEGF agents and steroids.
💡
Conclusion & Impact:In this review, treatments and new applications other than anti-VEGF, steroids and laser used in the treatment of central retinal vein occlusion and macular edema will be reviewed.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Many agents are used in the current treatment of central retinal vein occlusion and its complications. These treatments include anti- VEGF agents and steroids. Laser treatment is still up to date. In addition, many treatments are being developed outside the routine In addition, many treatments are being developed outside of the routine. In this review, treatments and new applications other than anti-VEGF, steroids and laser used in the treatment of central retinal vein occlusion and macular edema will be reviewed.

Özet

Santral retinal ven tıkanıklıkları ve komplikasyonlarının güncel tedavisinde birçok ajan kullanılmaktadır. Bu tedavilerin başında Anti-VEGF ajanlar ve steroidler yer almaktadır. Lazer tedavisi de halen güncelliğini korumaktadır. Ayrıca rutin dışında geliştirilmekte olan birçok tedavi üzerinde çalışılmaktadır. Bu derlemede santral retinal ven tıkanıklığı ve maküla ödemi tedavisinde rutinde kullanılan anti-VEGF, steroid ve lazer dışındaki tedaviler ve yeni uygulamalar gözden geçirilecektir.

🔖

Cite This Article

SONGUR, M. S., ÇITIRIK, M. (2019). Emerging Therapies for the Treatment of Central Retinal Vein Occlusion and Macular Edema. Güncel Retina Dergisi, Cilt: 3 - Sayı: 1, 56–59. https://ajindex.com/articles/159654

References (8)

  1. Klein R, Klein BE, Moss SE, Meuer SM. The epidemiology of retinal vein occlusion: The Beaver Dam Eye Study. Trans Am Ophthalmol Soc 2000;98:133– 141
  2. Branch Vein Occlusion Study Group. Argon laser scatter photocoagulation for prevention of neovascularization and vitreous hemorrhage in branch vein occlusion. A randomized clinical trial. Arch Ophthalmol 1986;104(1):34–41
  3. Rehak J, Rehak M. Branch retinal vein occlusion: pathogenesis, visual prognosis, and treatment modalities. Curr Eye Res. 2008;33(2):111–131. 4.Mitchell P, Smith W, Chang A. Prevalence and associations of retinal vein occlusion in Australia. The Blue Mountains Eye Study. Arch Ophthalmol. 1996;114(10): 1243–1247
  4. Bessette A, PK. Branch Retinal Vein Occlusion. Ryan’s Retina, Sixth Edition. Published January 1, 2018. Chapter 56, P;1155-1165. Clinical Key. Erişim tarihi 03.02.2018
  5. Hayreh SS, Zimmerman MB, Podhajsky P. Incidence of various types of retinal vein occlusion and their recurrence and demographic characteristics. Am J Ophthalmol 1994; 117(4):429–441
  6. Parodi MB, Bandello F. Branch retinal vein occlusion: Classification and treatment. Ophthalmologica 2009; 223(5):298–305. 8.Wong TY, Scott IU. Clinical practice. Retinal-vein occlusion. N Engl J Med. 2010; 363(22):2135–2144
  7. Kreutzer A, Brunner R, Schäfer HJ, Sickel W, Auel H, Hossmann V. [Thrombolytic therapy with recombinant tissue-type plasminogen activator in patients with branch or central vein occlusion of the retina]. Fortschr Ophthalmol. 1988;85(5):511-3. 10.Steinkamp GW, Hattenbach LO, Scharrer I, Ohrloff C. Front-loading RT PA thrombolytic therapy in central or venous branch occlusions of the retina. Ophthalmologe 1994; 91(3): 280–282 11. Weiss JN. Treatment of central retinal vein occlusion by injection of tissue plasminogen activator into a retinal vein. Am J Ophthalmol 1998;126(1):142– 144 12.Hattenbach LO, Steinkamp G, Scharrer I, Ohrloff C. Fibrinolytic therapy with low-dose recombinant tissue plasminogen activator in retinal vein occlusion. Ophthalmologica 1998;212(6):394–398 13. Hattenbach LO, Friedrich Arndt C, Lerche R, Scharrer I, Baatz H, Margaron F, et al. Retinal vein occlusion and low-dose fibrinolytic therapy (R.O.L.F.): a prospective, randomized, controlled multicenter study of low-dose recombinant tissue plasminogen activator versus hemodilution in retinal vein occlusion. Retina. 2009;29(7):932-40
  8. Murakami T, Takagi H, Kita M, Nishiwaki H, Miyamoto K, Ohashi H, et al. Intravitreal tissu